16 unknown. 16 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Unknown 16 |
| Phase 1 | 9 | Unknown 9 |
Follow Advanced Cancer: new trials by email Literature Review of Advanced Cancer trials Research Report on Advanced Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers BR1733 - Advanced Cancer, Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Blueray Biopharma Co., Ltd. | 191 | 2023-04-19 | 2024-08-07 |
| Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors EOS-448, pembrolizumab, inupadenant - Advanced Cancer, Lung Cancer | Phase 1 / Phase 2 | Unknown | iTeos Belgium SA | 153 | 2021-09-06 | 2024-06-21 |
| Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer PVT-1 - Non Small Cell Lung Cancer, Advanced Cancer | Phase 2 | Unknown | PlusVitech S.L. | 24 | 2021-03-10 | 2023-04-05 |
| A Prospective Dose Finding Study of Iscador Infusion Intravenous Solution - Advanced Cancer | Phase 1 / Phase 2 | Unknown | HaEmek Medical Center, Israel | 24 | 2020-12-01 | 2020-07-29 |
| Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma Toripalimab, Axitinib - Neoadjuvant Therapy, Advanced Cancer | Phase 2 | Unknown | West China Hospital | 40 | 2020-06-01 | 2020-05-13 |
| Study of the Apatinib Combine With POF Versus POF in Gastric Cancer Apatinib, POF - Gastric Adenocarcinoma, Advanced Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 116 | 2019-12-01 | 2019-10-09 |
| Clinical Study of Granulocyte Infusion for Advanced Cancer Granulocytes - Advanced Cancer | Phase 1 / Phase 2 | Unknown | Shanghai East Hospital | 100 | 2019-12-01 | 2019-12-19 |
| Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma Anlotinib Hydrochloride - Effect of Drugs, Quality of Life | Phase 2 | Unknown | Peking University People's Hospital | 60 | 2019-07-18 | 2019-08-05 |
| Apatinib Plus SHR1210 in Advanced Mucosal Melanoma apatinib plus SHR-1210 - Mucosal Melanoma, Advanced Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 40 | 2019-06-04 | 2019-06-14 |
| Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy Toripalimab - Small Cell Carcinoma of Esophagus, Advanced Cancer | Phase 2 | Unknown | Sun Yat-sen University | 43 | 2018-11-21 | 2019-01-23 |
| PEN-866 in Patients With Advanced Solid Malignancies PEN-866 Sodium, fluorouracil, Folinic acid - Carcinoma, Endometrial Adenocarcinoma | Phase 1 / Phase 2 | Unknown | Tarveda Therapeutics | 340 | 2017-08-29 | 2022-02-17 |
| Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma Nivolumab/Ipilimumab - Transitional Cell Carcinoma, Advanced Cancer | Phase 2 | Unknown | AIO-Studien-gGmbH | 169 | 2017-07-06 | 2021-11-03 |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies PD-1 antibody expressing mesothelin specific CAR-T cells - Solid Tumor, Adult, Advanced Cancer | Phase 1 / Phase 2 | Unknown | Ningbo Cancer Hospital | 40 | 2017-02-15 | 2017-01-24 |
| A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients SAF-189s - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 280 | 2016-11-14 | 2021-07-08 |
| Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors PM01183 + olaparib - Advanced Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Unknown | Poveda, Andrés, M.D. | 100 | 2015-07-01 | 2017-06-22 |
| An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer Atiprimod - Advanced Cancer | Phase 1 / Phase 2 | Unknown | Callisto Pharmaceuticals | 61 | 2005-03-01 | 2006-12-05 |
Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Anus Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Chordoma (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
Neoplasms (7) · Neoplasms by Site (6) · Neoplasms by Histologic Type (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Neoplasms (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplastic Processes (2)
apatinib (2) · toripalimab (2) · Axitinib (1) · Drug Evaluation (1) · Fluorouracil (1) · Ipilimumab (1) · Leucovorin (1) · Nivolumab (1) · PM 01183 (1) · azaspirane (1) · camrelizumab (1) · dostarlimab (1) · niraparib (1) · olaparib (1) · pembrolizumab (1)
AIO-Studien-gGmbH (1) · Callisto Pharmaceuticals (1) · Fujian Cancer Hospital (1) · HaEmek Medical Center, Israel (1) · Henan Cancer Hospital (1) · Ningbo Cancer Hospital (1) · Peking University People's Hospital (1) · PlusVitech S.L. (1) · Poveda, Andrés, M.D. (1) · Shanghai Blueray Biopharma Co., Ltd. (1) · Shanghai East Hospital (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Sun Yat-sen University (1) · Tarveda Therapeutics (1) · West China Hospital (1)
China (8) · United States (3) · Spain (2) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Andres Poveda, MD (1) · Anish Thomas, MD (1) · Donald Picker, PhD (1) · Gil Bar Sela, Prof (1) · Jing Ding, Master (1) · Marc-Oliver Grimm, Prof. Dr. (1) · Qijun Qian, PhD (1) · Rui-hua Xu, MD, PhD (1) · Sahin Lacin (1) · Wei Guo, M.D. and Ph.D. (1) · Yilong Wu, Doctor (1) · Zhongming Liu, MD/Ph.D (1)
PMID 32918045, PMID 35275706, PMID 36868252, PMID 38722641, PMID 39059398, PMID 42093981